ReviewClinical & experimental metastasis2026
Contribution of tumor-derived extracellular vesicles in the establishment of the pre-metastatic niche: lessons learned from past experimentations and future directions.
Review in Clinical & experimental metastasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diagnostic Potential of Selected Matrilysins and Stromelysins in the Diagnosis of Gynecological Malignancies Based on ROC Curve Analysis.International journal of molecular sciences · 2026Article
- Conditioned Media-Derived Tumor Extracellular Vesicles: Bridging Molecular Insights and Therapeutic Applications in Oncology.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Tumor-derived extracellular vesicles (TEVs) have been shown to actively contribute to the establishment of the pre-metastatic niche (PMN) through multiple mechanisms of action and the transfer of cargo material to host cells. Here, we report a review of 120 manuscripts published between January 2010 and April 2025 describing observations from in vivo experiments aimed at the examination of the contribution of TEVs to the PMN and the metastatic niche (MN). Whereas most of these publications reported observations made with models of exogenous administration of TEVs prepared in vitro, five publications used endogenous models of TEVs released by implanted tumors to track their fate and examine their role in the PMN. Breast and colon cancers and melanoma are the most common types studied, and lung, liver, bone, and lymph nodes are the most common sites of metastasis examined. Methods to isolate, characterize and label TEVs in exogenous models vary significantly with differential ultracentrifugation (DUC) being the most common method of isolation used, electron microscopy, nano tracking analysis (NTA) and western blotting being used for their characterization, and lipophilic dyes used for labeling. Immunodeficient and immunocompetent mice were used in the majority (94%) with some studies done in zebrafish. Single and multiple administrations of TEVs with doses ranging from 5 to 200 µg/mouse were reported. A review of the cells targeted by TEVs, the organs involved and the effects observed in the PMN and MN, led us to identify seven functional hallmarks: (1) Immune reprogramming, (2) Stromal cell activation, (3) Vascular permeability and angiogenesis, (4) Lymphatic remodeling and lymphangiogenesis, (5) Bone remodeling, (6) Extracellular matrix (ECM) remodeling and (7) Direct tumorigenicity. Altogether, these effects create an inflammatory and immunosuppressive microenvironment that favors tumor growth. Exogenous and endogenous models have both advantages and limitations and provide important complementary information. In both models, loss of function experiments aimed at determining whether TEVs are necessary for the formation of the PMN and MN represent an important challenge. Such experiments, however, will be critical to provide evidence that targeting TEVs could be a viable approach to inhibit or prevent metastasis in patients affected by cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.